OCULAR THERAPEUTIX INC (OCUL) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:OCUL • US67576A1007

9.495 USD
+0.33 (+3.66%)
Last: Feb 9, 2026, 03:06 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to OCUL. OCUL was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of OCUL is average, but there are quite some concerns on its profitability. While showing a medium growth rate, OCUL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year OCUL has reported negative net income.
  • In the past year OCUL has reported a negative cash flow from operations.
  • OCUL had negative earnings in each of the past 5 years.
  • OCUL had a negative operating cash flow in each of the past 5 years.
OCUL Yearly Net Income VS EBIT VS OCF VS FCFOCUL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -60.77%, OCUL is doing worse than 65.44% of the companies in the same industry.
  • OCUL's Return On Equity of -96.69% is on the low side compared to the rest of the industry. OCUL is outperformed by 62.83% of its industry peers.
Industry RankSector Rank
ROA -60.77%
ROE -96.69%
ROIC N/A
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
OCUL Yearly ROA, ROE, ROICOCUL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

  • OCUL has a better Gross Margin (88.87%) than 90.58% of its industry peers.
  • OCUL's Gross Margin has improved in the last couple of years.
  • OCUL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
OCUL Yearly Profit, Operating, Gross MarginsOCUL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • OCUL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OCUL has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for OCUL has been increased compared to 5 years ago.
  • The debt/assets ratio for OCUL has been reduced compared to a year ago.
OCUL Yearly Shares OutstandingOCUL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
OCUL Yearly Total Debt VS Total AssetsOCUL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 3.06 indicates that OCUL is not in any danger for bankruptcy at the moment.
  • OCUL has a better Altman-Z score (3.06) than 65.97% of its industry peers.
  • OCUL has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.27, OCUL is in line with its industry, outperforming 41.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 3.06
ROIC/WACCN/A
WACC10.09%
OCUL Yearly LT Debt VS Equity VS FCFOCUL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • OCUL has a Current Ratio of 7.85. This indicates that OCUL is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 7.85, OCUL is doing good in the industry, outperforming 72.77% of the companies in the same industry.
  • A Quick Ratio of 7.78 indicates that OCUL has no problem at all paying its short term obligations.
  • The Quick ratio of OCUL (7.78) is better than 73.30% of its industry peers.
Industry RankSector Rank
Current Ratio 7.85
Quick Ratio 7.78
OCUL Yearly Current Assets VS Current LiabilitesOCUL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • OCUL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.88%.
  • The Revenue has decreased by -9.21% in the past year.
  • The Revenue has been growing by 72.02% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
Revenue 1Y (TTM)-9.21%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-5.71%

3.2 Future

  • Based on estimates for the next years, OCUL will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.24% on average per year.
  • The Revenue is expected to grow by 55.79% on average over the next years. This is a very strong growth
EPS Next Y-1.87%
EPS Next 2Y0.33%
EPS Next 3Y7.21%
EPS Next 5Y17.24%
Revenue Next Year-14.17%
Revenue Next 2Y-1.97%
Revenue Next 3Y20%
Revenue Next 5Y55.79%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
OCUL Yearly Revenue VS EstimatesOCUL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
OCUL Yearly EPS VS EstimatesOCUL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • OCUL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year OCUL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCUL Price Earnings VS Forward Price EarningsOCUL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCUL Per share dataOCUL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.33%
EPS Next 3Y7.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • OCUL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OCULAR THERAPEUTIX INC

NASDAQ:OCUL (2/9/2026, 3:06:00 PM)

9.495

+0.33 (+3.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04
Earnings (Next)03-02
Inst Owners88.78%
Inst Owner Change1.84%
Ins Owners2.22%
Ins Owner Change4.52%
Market Cap2.02B
Revenue(TTM)55.78M
Net Income(TTM)-249.67M
Analysts86.32
Price Target24.82 (161.4%)
Short Float %6.18%
Short Ratio3.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.72%
Min EPS beat(2)-7.83%
Max EPS beat(2)-1.62%
EPS beat(4)0
Avg EPS beat(4)-12.26%
Min EPS beat(4)-26.63%
Max EPS beat(4)-1.62%
EPS beat(8)1
Avg EPS beat(8)-40.57%
EPS beat(12)4
Avg EPS beat(12)-25.42%
EPS beat(16)6
Avg EPS beat(16)-13.78%
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)-0.44%
Revenue beat(4)0
Avg Revenue beat(4)-10.82%
Min Revenue beat(4)-37.69%
Max Revenue beat(4)-0.44%
Revenue beat(8)1
Avg Revenue beat(8)-8.36%
Revenue beat(12)3
Avg Revenue beat(12)-6.11%
Revenue beat(16)3
Avg Revenue beat(16)-8.25%
PT rev (1m)0%
PT rev (3m)15.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.63%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 36.26
P/FCF N/A
P/OCF N/A
P/B 7.83
P/tB 7.83
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.26
BVpS1.21
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.77%
ROE -96.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.87%
FCFM N/A
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 232.75%
Cap/Sales 16.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.85
Quick Ratio 7.78
Altman-Z 3.06
F-Score2
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)138.13%
Cap/Depr(5y)98.78%
Cap/Sales(3y)6.55%
Cap/Sales(5y)5.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
EPS Next Y-1.87%
EPS Next 2Y0.33%
EPS Next 3Y7.21%
EPS Next 5Y17.24%
Revenue 1Y (TTM)-9.21%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-5.71%
Revenue Next Year-14.17%
Revenue Next 2Y-1.97%
Revenue Next 3Y20%
Revenue Next 5Y55.79%
EBIT growth 1Y-77.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-59.56%
EBIT Next 3Y5.35%
EBIT Next 5Y19.4%
FCF growth 1Y-175.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-193.62%
OCF growth 3YN/A
OCF growth 5YN/A

OCULAR THERAPEUTIX INC / OCUL FAQ

What is the ChartMill fundamental rating of OCULAR THERAPEUTIX INC (OCUL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to OCUL.


Can you provide the valuation status for OCULAR THERAPEUTIX INC?

ChartMill assigns a valuation rating of 0 / 10 to OCULAR THERAPEUTIX INC (OCUL). This can be considered as Overvalued.


How profitable is OCULAR THERAPEUTIX INC (OCUL) stock?

OCULAR THERAPEUTIX INC (OCUL) has a profitability rating of 1 / 10.


What is the earnings growth outlook for OCULAR THERAPEUTIX INC?

The Earnings per Share (EPS) of OCULAR THERAPEUTIX INC (OCUL) is expected to decline by -1.87% in the next year.